{"id":"W4288987527","doi":"10.1016/j.esmoop.2022.100530","title":"Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"EMD Serono; Genentech; Relay Therapeutics; Tessa Therapeutics; Aptose Biosciences; Banco Bilbao Vizcaya Argentaria; BeiGene; Jounce Therapeutics; Lilly Oncology; Bayer Fund; Mirati Therapeutics; Halozyme; Regeneron Pharmaceuticals; Boston Scientific Corporation; Fundación BBVA; F. Hoffmann-La Roche; AbbVie; Novartis; Celgene; Medtronic; Fundación Cellex; Les Laboratories Pierre Fabre; Meso Scale Diagnostics; Sanofi; Mersana Therapeutics; Merck; GlaxoSmithKline; Eli Lilly and Company; “la Caixa” Foundation; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Amgen; Boehringer Ingelheim; Pfizer; National Cancer Institute; Servier; Gilead Sciences; Taiho Pharmaceutical; Conquer Cancer Foundation","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Adverse effect; Immunogenicity; Oncology; Internal medicine; Cancer; Antibody; Response Evaluation Criteria in Solid Tumors; Pharmacology; Monoclonal antibody; Toxicity; Phases of clinical research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000308485,0.0002167367,0.0007174183,0.000268473,0.0004567901,0.00003863281,0.0003936097,0.00003658789,0.001783402],"category_scores_gemma":[0.00008623273,0.000215218,0.0001560526,0.0002587423,0.00004138568,0.0002195468,0.0004160216,0.0003783001,0.000005054398],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003234085,"about_ca_system_score_gemma":0.0002664243,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001699494,"about_ca_topic_score_gemma":0.0005096142,"domain_scores_codex":[0.9981633,0.00007442494,0.0006850803,0.0004535057,0.0003228128,0.0003008057],"domain_scores_gemma":[0.9989611,0.0001100675,0.0002888673,0.0004197149,0.0001188275,0.0001014339],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004614586,0.01930672,0.02816386,0.0002353111,0.0004220566,0.0003910822,0.01064173,0.001452356,0.9279683,0.0003068229,0.004965814,0.001531358],"study_design_scores_gemma":[0.2088132,0.05731695,0.1363311,0.001201642,0.0005940264,0.0002446232,0.02960068,0.006828301,0.4943366,0.0003467879,0.06248858,0.001897501],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953094,0.00002683995,0.00003806256,0.0001100881,0.0003241047,0.003058037,0.0001995513,0.00003868405,0.0008952142],"genre_scores_gemma":[0.9980725,0.0000029736,0.0002221278,0.0001041931,0.0001243824,0.0004712653,0.0002627345,0.00005113359,0.0006886661],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4336317,"threshold_uncertainty_score":0.9991291,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05214843498204853,"score_gpt":0.4088325772980611,"score_spread":0.3566841423160125,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}